#Cincinnati #CAR-T therapy #Cincinnati Children's #BioOra

BioOra and Cincinnati Children's Partnership in Advancing CAR-T Therapy for Children

BioOra Limited, a leading cell therapy company based in Wellington, New Zealand, has entered into a significant partnership with Cincinnati Children's Hospital Medical Center to take strides in the evaluation and advancement of Atla-cel (atlacabtagene autoleucel). This therapy, designed specifically for paediatric patients grappling with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL), is built upon encouraging clinical data gathered from adult patients.

The Challenge of Treating Paediatric B-ALL

Children diagnosed with relapsed or refractory B-ALL often experience daunting challenges when it comes to treatment options. Despite notable advancements in frontline therapies, the prognosis for these young patients remains grim. Traditional CAR-T therapies, although proven effective, are often encumbered by severe side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Such conditions necessitate intensive inpatient care, which can prove to be particularly burdensome for both patients and their families.

Advancements with Atla-cel

The Atla-cel therapy aims to address these concerns through a highly refined third-generation CAR-T approach, specifically targeting CD19. Early findings from the Phase 1 ENABLE-1 study, presented at the 2024 American Society of Hematology Annual Meeting, highlight Atla-cel’s encouraging safety profile, showcasing narrower rates of both serious CRS and notably reduced ICANS when compared to its predecessors.

For children, ICANS is not merely a risk; it is a critical concern that complicates the use of CAR-T therapies. The data suggesting low incidences of ICANS in adult patients presents a strong case for trialing this therapy in a paediatric setting, where it could potentially lead to outpatient delivery options, reducing the need for extended hospital stays.

The Partnership Dynamics

Cincinnati Children's Hospital stands out as a premier academic medical institution equipped with extensive expertise in paediatric haematology, oncology, and cellular therapy. This collaboration will leverage clinical data from the ENABLE trial conducted by BioOra together with the Malaghan Institute of Medical Research in New Zealand.

To strengthen this collaboration, Steve Davis, MD, the President and Chief Executive Officer of Cincinnati Children's, will join the Board of Directors at BioOra, thereby fostering synergy between the two organizations as they aim to make significant advancements in CAR-T therapy for young patients.

Clinical Program Overview

The innovative approach to the B-ALL clinical program will roll out across the United States, New Zealand, and possibly Australia, under the meticulous management of Cincinnati Children's. Dr. Stella M. Davies, a highly esteemed figure in paediatric haematology-oncology, will spearhead the study. Her leadership, complemented by Cincinnati Children's reputation as the top cancer care provider in the United States, promises a rigorous and insightful evaluation of Atla-cel.

Expert Insights

Laurence Cooper, MD, PhD, a paediatric oncologist with BioOra, emphasized the importance of providing children with regimens that are both effective and bear a lower risk profile.